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Abstract
Background—Early-life lead (Pb) exposure induces overexpression of the amyloid beta
precursor protein and its amyloid beta product in older rats and primates. We exposed rodents to
Pb during different life span periods and examined cognitive function in old age and its impact on
biomarkers associated with Alzheimer’s disease (AD).
Methods—Morris, Y, and the elevated plus mazes were used. Western blot, quantitative
polymerase chain reaction (qPCR), and enzyme-linked immunosorbent assay were used to study
the levels of AD biomarkers.
Results—Cognitive impairment was observed in mice exposed as infants but not as adults.
Overexpression of AD-related genes (amyloid beta precursor protein and β-site amyloid precursor
protein cleaving enzyme 1) and their products, as well as their transcriptional regulator—
specificity protein 1 (Sp1)—occurred only in older mice with developmental exposure to Pb.
Conclusions—A window of vulnerability to Pb neurotoxicity exists in the developing brain that
can influence AD pathogenesis and cognitive decline in old age.
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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia affecting elderly people.
The main characteristic features of AD include accumulation of senile plaques composed of
aggregated amyloid beta (Aβ), neurofibrillary tangles enriched with phosphorylated tau, and
synaptic loss in the brain resulting in cognitive decline [1,2]. Although the familial form of
AD is determined genetically, late-onset AD (LOAD) is sporadic and represents ~95% of
AD cases. In addition, it is unknown whether the onset of events that result in LOAD are
part of aging or have earlier developmental beginnings.
Previous reports by us on both rodents and primates have shown that early life exposure to
the environmental metal lead (Pb) resulted in a latent overexpression of genes and proteins
associated with the amyloid pathway, and enhancement of AD pathology in primates [3,4].
Recently, we have also found that both total tau and its phosphorylated forms, as well tau
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deposits, were elevated in both aging rodents and primates previously exposed to Pb as
infants (data under publication review). These findings provide evidence that molecular
events occurring during critical periods of brain development are reprogrammed by
environmental exposure to promote AD-like pathogenesis late in life. Also, we have
reported genomewide messenger RNA (mRNA) expression profiling and methylomic
analysis that reveal the scope of reprogramming of gene expression in the aging brain as a
result of early life exposure and its connection to epigenetic mechanisms acting at the
developmental stage [5,6].
Epidemiologic data that demonstrate a link between early life exposure to an environmental
agent and LOAD are limited. The Normative Aging Study investigated the link between past
nonoccupational Pb exposure and cognitive decline. Investigators reported that higher levels
of Pb in blood and/or bone were accompanied by poor cognitive performance in different
cognitive tests, including the Wechsler Adult Intelligence Scale–Revised, the Consortium to
Establish a Registry for Alzheimer’s Disease and the Mini-Mental State Examination [7–
10]. In a subgroup of the Nurses’ Health Study, Weuve and colleagues [11] reported that
higher levels of Pb in the tibia was associated with poor test scores on the Mini-Mental State
Examination.
Multiple animal studies by us have demonstrated a link between early life exposure to this
environmental agent and amyloidogenesis in old age [3,4,12]; however, although these
studies are compelling, behavioral analysis was lacking to demonstrate the functional impact
of early exposure on cognition in old age. Here we present the findings from a 2-year life
span study in rodents that tested the impact of Pb exposure on cognitive function in the
aging rodent brain, and examined its relationship to critical periods of exposure (both
developmental and adult) and their impact on biochemical and molecular pathways
associated with AD pathogenesis in the same cohort of animals.
2. Methods
2.1. Animal exposure
C57BL/6 mice were bred in-house at the University of Rhode Island. Postnatal day 1 (PND
1) was designated as 24 hours after birth. All pups were pooled, and new litters consisting of
10 males were selected randomly and placed with each dam. The animals were divided into
four groups. The control group received regular tap water. The second group (PbE, the early
Pb exposure group) was exposed to 0.2% Pb acetate from PND 1 to PND 20 through
drinking water of the dam. The third group (PbA, the adult lead exposure group) was
exposed to Pb daily for 3 months starting at 7 months of age. The fourth group (PbEA, the
early and adult Pb exposure group [reexposure as adults]) was exposed to Pb
developmentally (PND 1 to PND 20) and during adulthood (7–9 months of age). Brains
were dissected at different ages—eight mice at PNDs 20, 180, 270, 540, and 700—and brain
frontal cortex tissues were stored at −80°C until use.
2.2. Behavioral tests
Behavioral testing was conducted on selected time points (PND 540 and PND 700). To
assess spatial learning and memory (a hippocampal formation-dependent task), animals were
tested in the Morris water maze task and for the transfer latency (TL) in the elevated plus
maze. Measuring the spontaneous alternations in the Y maze also assessed working memory
function.
2.2.1. Morris water maze—The test was performed following the method of Morris and
colleagues [13]. Each animal received three trials per day for 7 days with a 20-minute
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intertrial interval. A retention test (probe trail) was performed on the eighth day, and the
percentage of time and distance traveled in the target quadrant for 60 seconds was recorded.
Swim distance and latencies to locate the platform were videotaped and analyzed with a
computerized video tracking system (ObjectScan, Clever Systems Inc.). Training and
retention tests were conducted between 0900 HR and 1600 HR.
2.2.2. Y maze training procedure—Spontaneous alternation was tested in the Y maze,
which consists of three white, opaque plastic arms at a 120° angle from each other. The
ability to alternate requires that the mice know which arms have already been visited.
Therefore, alternation behavior can be regarded as a measure of spatial working memory
[14]. During the test session, each mouse was placed at the end of one arm and allowed to
move freely through the maze during a 10-minute session. The total number of arm entries
(locomotor activity) and alternations (defined as consecutive entries into all three arms
without repetitions, in overlapping triplet sets) were scored.
2.2.3. Elevated plus maze—TL was tested using an elevated plus maze consisting of
two open arms (30 × 5 × 2.5 cm) and two enclosed arms (30 × 5 × 15 cm). The maze was
elevated to the height of 50 cm. Mice were placed individually at the end of an open arm
facing away from the central platform, and the time it took to move from the end of the open
arm to either of the closed arms (TL) was recorded. The TL was expressed as retention after
24hours by calculating the inflexion ratio (IR) using the formula
where IR is the inflexion ratio, L0 is the TL after 24 hours, and L1 is the initial TL in
seconds.
2.3. Western blotting
Cerebral cortical tissues were homogenized in RIPA buffer containing a protease inhibitor
cocktail (Sigma-Aldrich), incubated on ice for 1 hour, then centrifuged at 3500 g for 20
minutes [3]. The supernatant was collected and used for Western blot analysis. Protein
concentration was determined by using a BCA kit (Pierce Biotechnology Inc.Rockford, IL,
USA). For amyloid beta precursor protein (AβPP) and specificity protein 1 (Sp1) proteins,
40 μg protein was separated via 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Nonspecific binding was blocked by incubation with 5% bovine serum
albumin (BSA) in Tris buffer Saline + 0.1% Tween 20 (TBST) at room temperature for 1
hour. Immunoblotting was performed after overnight exposure to the following antibodies
diluted at 1:1000 with gentle agitation on a shaker at 4°C: AβPP (anti-Alzheimer precursor
protein A4, amino acids 66–81 of AβPP [N-terminus], clone 22C11 mouse monoclonal) and
anti-Sp1 rabbit polyclonal (Millipore, Billerica, MA, USA). On the following day,
membranes were washed and exposed for 1 hour to IRDye 680LT Infrared Dye (LI-COR
Biotechnology, Lincoln, NE, USA), goat antimouse/goat antirabbit diluted at 1:10,000. The
images were developed using an Odyssey infrared imaging system (model 9120; LI-COR
Biotechnology, Lincoln, NE, USA). As a control for equal protein loading, membranes were
stripped and reprobed with rabbit β-actin antibody (diluted at 1:2500; Sigma-Aldrich, St.
Louis, MO, USA) and exposed to antirabbit IRDye 680LT Infrared Dye. After transferring
to a polyvinylidene difluoride membrane, the gel was stained with Bio-safe Coomassie blue
stain (Bio-Rad, Hercules, CA, USA) to assess the loading of the samples.
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2.4. Total RNA isolation, synthesis of complementary DNA, and real-time polymerase chain
reaction
RNA from the brain tissue was isolated according to the TRIzol method (Invitrogen). First-
strand complementary DNA (cDNA) was synthesized from 1.5 μg total RNA using the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). cDNA was then amplified using
real-time polymerase chain reaction. The SYBR Green quantitative real-time polymerase
chain reaction assay was performed in 25-μL reactions in triplicate using 1.5 μL cDNA
template, 1 × SYBR Green master mix, 0.4 μM forward and reverses primers, and deionized
H2O. The following primers were used: AβPP forward primer, 5′-GGT TCT GGG CTG
ACA AAC AT-3′; AβPP reverse primer, 5′-GTG ATG ACA ATC ACG GTT GC-3′; Sp1
forward primer, 5′-TCA TAC CAG GTG CAA ACC AA-3′; Sp1 reverse primer, 5′-AGG
TGA TGT TCC CAT TCA GG-3′; β-site amyloid precursor protein (APP) cleaving enzyme
1 (BACE1) forward primer, 5′ ATG TGC ACG ATG AGT TCA GG-3′; and BACE1
reverse primer, 5′-GCA GAG TGG CAA CAT GAA GA-3′. Amplification was undertaken
on an ABI PRISM 7500 machine (Applied Biosystems, Foster City, CA, USA) with
sequence detection software version 1.3, and expression was reported relative to
glyceraldehyde-3-phosphate dehydrogenase mRNA with the 2−ΔΔCt method.
2.5. Enzyme-linked immunosorbent assay Aβ (1–40) and Aβ (1–42)
The levels of Aβ were measured using human Aβ (1–40) and (1–42) assay kits. These kits
are solid-phase sandwich enzyme-linked immunosorbent assays with two kinds of highly
specific antibodies, which are 100% reactive with mouse Aβ1–40 and 70% reactive with
mouse Aβ1–42. The assay was conducted according to the manufacturer’s instructions
(Immuno-Biological Laboratories, Gunma, Japan) with minor modifications [15]. One
hundred micrograms of protein samples in 100 μL EIA buffer and assay standards were
added to 96-well plates precoated with anti-human Aβ mouse immunoglobulin G
monoclonal antibody. The plates were incubated overnight at 4°C, and were washed seven
times using the 40× diluted wash buffer supplied with the kit (0.05% Tween 20 in phosphate
buffer). Afterward, 100 μL labeled antibody were added to the samples and standards,
followed by incubation at 4°C for 1 hour. After incubation, the plates were washed nine
times followed by the addition of 100 μL tetramethylbenzidine as a coloring agent. The
plates were incubated in the dark for 30 minutes at room temperature. Last, 100 μL 1 N
H2SO4 was added to stop the reaction, and absorbance was measured at 450 nm using a
Spectra Max UV/Vis Spectrometer (GMI, Inc.). The levels of Aβ in the test samples were
calculated relative to the standard curve generated for each plate.
2.6. BACE1 activity assay
β-Secretase activity was measured with a BACE1 activity kit (SensiZyme BACE1 Activity
Assay Kit, Sigma-Aldrich, Saint Louis, MO, USA) according to the manufacturer’s
protocol. The enzymatic reactionfor secretase activity was carried out in an anti-BACE1-
coated 96-well plate. The 100 μL of standards and test samples were pipetted into each well
and incubated for 2 hour at 2°C to 8°C. The solution was aspirated from the wells and
washed four times with wash buffer. A 50-μL substrate (proenzyme) was added to each well
and was incubated overnight at room temperature in a humidified chamber. On the
following day, 50 μL reagent mixture (substrate B + dithiothreitol (DTT) was added to each
well followed by shaking for 20 seconds. The plate was incubated again at room temperature
for a couple hours and then absorbance was measured at 405 nm using a plate reader. The
activity of BACE1 is presented in nanograms per milliliter.
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2.7. Statistical analysis
Western blot bands were quantified by using the LI-COR/Odyssey infrared image system.
All measurements were made in triplicate and all values are presented as mean ± standard
error of the mean. The significance of the difference among means of the experimental
groups was obtained with one-way analysis of variance, the Tukey-Kramer multiple-
comparison posttest, and the student Newman-Keuls comparison posttest, using Graph pad
Prism 3.0 computer software(La Jolla, CA, USA). The level of significance was set at P <.
05.
3. Results
3.1. Effect of developmental Pb exposure on performance in the Morris water maze
The Pb exposure model that we have used in several life span studies does not result in
nutritional disturbances, as evidenced by the absence of changes in weight or any overt
changes in brain structure or anatomy. The death rate of the aging animals was not any
different from that in controls [3,6]. The Pb levels in the two age groups, PND 20 and PND
700, have been monitored and published in previous studies [16]. We found that at 20 days
after exposure, the Pb blood level was 46.13 ± 1.95 μg/dL and the brain level were 0.41 ±
0.04 μg/g wet weight. Pb levels in the aging animals are at background levels in both the
control and animals with prior exposure to Pb.
Exposure of mice to the developmental neurotoxicant Pb under different scenarios was
tested in the spatial learning tasks of the Morris water maze at PND 540 and PND 700.
Learning, assessed by the reduction in latency to find the hidden platform during 7 days of
training, was clearly evident for the control and PbA groups, and was no different at PND
540 and PND 700 for these groups. However, our results indicate that mice from the PbE
(developmental exposure only) and PbEA (developmental and adult exposure) groups,
which were tested at PND 540, exhibited a significant (P < .05) increase in latency at day 7
of training (Fig. 1A). Likewise, mice from the PbE and PbEA groups, which were tested at
PND 700, showed a significant delay (P <.05, P <.01) in latency from day 2, which was
consistent until day 6 of training compared with age-matched controls; these mice never
found the platform within 20 seconds during the acquisition phase (Fig. 2A). The deficit in
memory was also confirmed in the PbE and PbEA groups by probe tria ls undertaken on day
8. A significant decrease (P <.05, P <.01) in the percentage time spent and distance traveled
in the target quadrant was observed in these mice at PND 540 (Fig. 1B, C), and memory
deficiency was observed to be most significant (P <.001) at PND 700 compared with aged-
matched controls (Fig. 2B, C).
3.2. Effect of early life Pb exposure on Y maze performance and TL
Analysis of the results from the Y maze task of the four groups at time points PND 540 and
PND 700 reveal a significant (P <.05, P <.01) reduction in the spontaneous alternation in the
PbE and PbEA groups at both time points of analysis (Fig. 3A, B). Similarly, TL of first day
reflected learning behavior of animals, whereas TL of second day reflected retention of
information, or memory. Our results revealed a significant (P <.05, P <.01) decrease in the
inflexion ratio of the PbE and PbEA groups at time points PND 540 and PND 700 compared
with the control group (Fig. 3C, D).
3.3. Latent protein expression of A β PP and Sp1
The protein expressions of AβPP and Sp1 relative to β-actin were profiled by Western
blotting at different time points during the life span of the experimental mice. Normalized
AβPP levels in the PbE and PbEA groups compared with the control group were found to
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slightly increase during development, remained steady during adulthood, and increased
significantly (P <.05) in old age (Fig. 4A, B). Similarly, normalized Sp1 levels in the PbE
and PbEA groups displayed an increase on PND 20, which showed a significant (P < .05)
increase in old age (Fig 5A, B). No significant change in the protein expression of AβPP and
SP1 was observed in the PbA group.
3.4. Effect of aging and developmental exposure of Pb on Aβ levels and BACE1 activity
Changes in Aβ1–40 and Aβ1–42 levels were examined by enzyme-linked immunosorbent
assay at PNDs 20, 180, 270, 540, and 700. Our results revealed that the PbA group displayed
no change in Aβ levels at various time points of analysis. On the other hand, an increase in
the levels of Aβ1–40 and Aβ1–42 was observed in the PbE and PbEA groups at PND 270,
which was significantly pronounced (P <.05) on PND 700 (Fig. 6A, B). The ratio of Aβ1–42
to Aβ1–40 on PND 20 and PND 700 for the PbE and PbEA groups displayed a significant
(P <.05) increase at PND 20 compared with age-matched groups, with a greater change in
the ratio at PND 700 (P < .001). The PbA group did not show any significant change in the
ratio at PND 20 or PND 700 (Fig. 6C). Our results further demonstrate a significant (r =
−0.42, P <.03) correlation between Aβ1–40 levels and the percentage of time spent in the
correct quadrant during the probe trial in the water maze task for 700-day-old mice. A
correlation between Aβ1–42 and percentage of time spent in the correct quadrant during the
probe trial in the water maze by same age group showed a similar trend (r = −0.389, P <.06).
BACE1 is the proteolytic enzyme that generates the N-terminus of the Aβ peptide. Our
study shows that BACE1 activity in the control and PbA groups remained relatively steady
in young and aging mice. Developmental exposure of mice to Pb was found to induce a
significant (P < .05) increase in the BACE1 activity in the PbEA group at PND 500. A
significant increase was also evident in the PbE and PbEA groups at PND 700 compared
with age-matched controls (Fig. 6D).
3.5. Effect of aging and Pb exposure on AβPP, BACE1, and Sp1 mRNA expression
In the five age groups studied, normalized AβPP, BACE1, and Sp1 mRNA expression was
evaluated for control as well as mice with stage-specific exposure to Pb. Our results indicate
that the PbE and PbEA groups showed a significant (P < .05) latent upregulation of mRNA
expression of AβPP (Fig. 4C), Sp1 (Fig. 5C), and BACE1 (Fig. 6E) at PND 700 compared
with aged-matched controls. No significant change in mRNA expression was observed in
the PbA group compared with the control group.
4. Discussion
Heavy metals such as Pb pose a widespread environmental concern, and persistent human
exposure to low levels of Pb has been a matter of public concern worldwide [17]. Exposure
to Pb is the most prevalent, and Pb is the most insidious environmental toxin affecting
children, particularly during the perinatal stage. Children have been found to be cognitively
impaired at blood levels below the Centers for Disease Control and Prevention safe level of
10 μg/dL [18,19]. Although, exposure to Pb is widely recognized to be a risk factor for the
health of children and adults, our studies are the first to reveal that early life exposure has a
latent effect on neurodegenerative diseases [4,6], thereby providing the first environmental
model of early life exposure that predetermines outcomes of the aging brain through
epigenetic reprogramming [6].
Previous studies by us focused on molecular and biochemical changes in old age resulting
from infantile exposure to Pb. In the current study, we conducted comprehensive behavioral
testing on aging animals exposed exclusively to Pb during the early developmental stage
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and/or reexposed again as adults. The performance of these animals was compared with
siblings with no exposure (controls) or siblings exposed as adults only (PbA). Animals with
a developmental component of exposure were impaired in their performance at 18 months of
age, which was much pronounced at 24 months (Figs. 1 and 2), whereas animals exposed as
adults only performed similar to controls. In the Y maze test as well, animal groups with a
developmental component of exposure showed a decrease in spontaneous alternations at
PND 540 and PND 700 compared with age-matched controls (Fig. 3A, B). These findings
demonstrate that the perinatal developmental stage is a critical period of exposure and has an
effect on cognitive function later in life.
Past reports from our laboratory have demonstrated that AβPP mRNA and protein
expression in the cerebral cortex increase with age and are abnormally elevated in older rats
or primates exposed to Pb as infants [3,4]. Similar results were also observed in an in vitro
study in which differentiated SH-SY5Y cells were exposed to Pb early and were allowed to
live for about a month [20]. Consistent with the earlier studies, control animals, which
represent normal aging, displayed an increase in APP expression in late life; however, mice
exposed to Pb during developmental phases showed a drastic increase in the protein and
mRNA levels of APP. This latent increase in APP was also accompanied by commensurate
elevation in Aβ levels. The ratio of Aβ1–42 to Aβ1–40 in rodents with developmental
exposure to Pb was also found to be significantly elevated late in life [3,4].
Furthermore, consistent with our earlier findings, a significant increase in BACE1 activity
and mRNA levels was observed in mice exposed to Pb as pups [21]. Sp1 was also similarly
increased late in life (Fig. 5), commensurate with the role of Sp1 as an essential regulator of
the AβPP gene [3,22,23], and is in agreement with previous findings[21,24]. What is striking
is that the changes in the AD-related genes and their products mirror the behavioral
outcomes, supporting the hypothesis that there is a developmental window of vulnerability
to low levels of Pb exposure.
Although no direct evidence is presented vis-à-vis the latent cognitive deficits and latent
alterations in the amyloid pathway, supporting evidence for the relationship between the
amyloidogenic pathway and the decline in cognitive capacities late in life are as follows: (1)
both the cognitive decline and the alterations in amyloid intermediates occur late in life, (2)
the life span profiles of the amyloid intermediates are not altered in animals unexposed
during development nor is there any cognitive decline in animals exposed as adults only, and
(3) correlational analysis of some behavioral tasks suggests a possible relationship. Thus,
these findings suggest that cognitive deficits occurring in old age are related to alterations in
the status of the amyloid pathway as a result to developmental Pb exposure.
To explain these latent changes in gene expression, the proposed mechanisms must include
long-term epigenetic modification in the structural architecture of the DNA bases that
regulate the accessibility of transcription factors to these genes. Past reports have revealed
that Sp1, BACE, and APP genes are rich in cytosine-phosphate-guanine (CpG) dinucleotide
and guanine-cytosine (GC) box elements [25], thus making them targets for epigenetic
modification via DNA methylation. These characteristic features of the AβPP gene and the
other AD-related genes such as BACE, previously shown by us to be altered late in life as a
result of early-life Pb exposure, suggest that the genes with promoters that are rich in CpG
dinucleotides can be the prime candidates for epigenetic reprogramming. The reduced
activity and protein levels of DNA methylating enzymes DNMT1 and DNMT3 A, which we
observed in aging animals as well as in cultured cells that had prior exposure to Pb [21,26],
is consistent with the upregulation of some genes observed in old age. Furthermore, recent
discoveries that DNMT3 A levels are directly related to cognitive decline in old age lends
more support to this hypothesis, especially because this enzyme is also regulated
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developmentally [27]. However, both upregulation and downregulation of genes occur in
older animals exposed to Pb as infants and, in either case, DNA methylation appears to play
an important role [6]. Hence, early-life exposure to Pb interferes with DNA methylation
patterns of genes, which is then sustained throughout life and has an impact during old age.
In conclusion, our results indicate that early exposure to the environmental toxicant Pb
causes a significant cognitive deficit late in life that is accompanied by latent upregulation in
AD biomarkers AβPP, Aβ, and BACE1. This study demonstrates that development is an
important period that is vulnerable to environmental toxicants, which could increase future
disease susceptibility, including AD, potentially through epigenetic reprogramming.
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RESEARCH IN CONTEXT
1. Systematic review: We have conducted a literature review and together with our
previous reports we established a link between early life exposure and
amyloidogenesis. While previous studies focused on molecular and biochemical
changes, we sought to investigate the functional impact of early life exposure on
behavioral outcomes on aging animals. In addition, we examined the changes on
amyloidogenic proteins following early and adult exposure to lead at multiple
time points during the life span of mice.
2. Interpretation: These findings affect the early origins of AD and support
environmental metal lead as a risk factor for AD and cognitive decline in old
age. The data provides further evidence that the developmental stage is
vulnerable to environmental toxicants leading to increase in disease
susceptibility in adulthood.
3. Future directions: the current study provides evidence of a relation between
early life exposure to lead and cognitive changes at old age. While we have
examined the changes in the amyloidogenic pathway, it is important to further
study lead’s effects on the other hallmark of AD, tau pathology. In addition, it is
crucial to investigate the possible mechanisms leading to those changes,
including epigenetic reprogramming.
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Fig. 1.
Acquisition and memory retention in 18-month old mice. Training in the Morris water maze
consisted of three trials per day for 7 days to locate a hidden platform. Memory retention
was assessed by a 60-secoond probe trial 24 hours after the last day of acquisition testing.
(A) Mean escape latencies for finding the platform during daily training sessions. (B) Probe
trial data representing the time spent in the target quadrant where the platform was located
during training. (C) Probe trial data representing the distance traveled in the correct
quadrant. Values are expressed as mean ± standard error of the mean. *P <.05 compared
with control. **P <.01 compared with control. PbA, adult lead exposure group; PbE, early
lead exposure group; PbEA, early and adult lead exposure group.
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Fig. 2.
Acquisition and memory retention in 24-month-old mice. Training in the Morris water maze
consisted of three trials per day for 7 days to locate a hidden platform. Memory retention
was assessed by a 60-second probe trial 24 hours after the last day of acquisition testing. (A)
Mean escape latencies for finding the platform during daily training sessions. (B) Probe trial
data representing the time spent in the target quadrant, where the platform was located
during training. (C) Probe trial data representing the distance traveled in the correct
quadrant. Values are expressed as mean ± standard error of the mean. *P <.05 compared
with control. **P <.01 compared with control. ***P <.001 compared with control. PbA,
adult lead exposure group; PbE, early lead exposure group; PbEA, early and adult lead
exposure group.
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Fig. 3.
Developmental exposure to Pb affects spontaneous alternations and transfer latency in older
mice. (A, B) Mice were tested for spatial working memory as measured by assessing the
spontaneous alternations in Y maze at 18 months of age (A) and at 24 months of age (B). (C,
D) Retention memory using the transfer latency as a parameter for acquisition and retention
memory expressed as the inflexion ratio were also assessed in the elevated plus maze at 18
months of age (C) and 24 months of age (D). Data was expressed as mean ± standard error
of the mean. *P <.05 compared with control. **P <.01 compared with control. PbA, adult
lead exposure group; PbE, early lead exposure group; PbEA, early and adult lead exposure
group.
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Fig. 4.
Amyloid-β precursor protein (AβPP) expression across the life span and after developmental
exposure to lead (Pb). (A) Changes in life span profiles of AβPP protein expression in the
cerebral cortex of control (Control), early Pb exposure group (PbE), adult Pb exposure group
(PbA), and early and adult Pb exposure group (PbEA) measured by Western blot analysis as
described in Methods. (B) Quantification of AβPP Western blot bands normalized to β-actin
levels. (C) Life span messenger RNA (mRNA) levels of AβPP relative to glyceraldehyde-3-
phosphate dehydrogenase. Each data point in the curve is the mean ± standard error of the
mean. *P <.05 compared with control.
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Fig. 5.
Specificity protein 1 (Sp1) life span expression profiles and levels in mice cortex with
infantile exposure to lead (Pb). (A) Changes in the life span profiles of Sp1 were measured
in the cerebral cortex of the control (Control), early Pb exposure group (PbE), adult Pb
exposure group (PbA), and early and adult Pb exposure group (PbEA) using Western blot
analysis as described in Methods. (B) Quantification of SP1 Western blot bands after
normalization to β-actin levels. (C) Life span messenger RNA (mRNA) levels of Sp1
relative to glyceraldehyde-3-phosphate dehydrogenase. Each data point in the curve is the
mean ± standard error of the mean SEM. *P <.05 compared with control.
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Fig. 6.
β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) activity, BACE1 messenger
RNA (mRNA) levels, and amyloid beta (Aβ) life span expression profiles in mice cortex
with infantile exposure to lead (Pb). (A, B) Changes in the life span profiles of Aβ1–40 (A)
and Aβ1–42 (B). (C) The ratio of Aβ1–42 to Aβ1–40 in postnatal day (PND) 20 and PND
700 mice using enzyme-linked immunosorbent assay as described in Methods. (D) Changes
in BACE1 activity were measured in the cerebral cortex of the control (Control), early Pb
exposure group (PbE), adult Pb exposure group (PbA), and early and adult Pb exposure
group (PbEA). (E) Life span mRNA levels of BACE1 relative to glyceraldehyde-3-
phosphate dehydrogenase. Values are expressed as mean ± standard error of the mean. *P <.
05 compared with the control group. ***P <.001 compared with the control group.
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